- Report
- October 2023
- 80 Pages
Poland
From €1365EUR$1,500USD£1,160GBP
- Report
- October 2023
- 80 Pages
Japan
From €1365EUR$1,500USD£1,160GBP
- Report
- October 2023
- 80 Pages
Argentina
From €1365EUR$1,500USD£1,160GBP
- Report
- January 2025
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Report
- April 2024
- 132 Pages
Global
From €865EUR$950USD£734GBP
- Report
- November 2022
- 310 Pages
Global
From €2447EUR$2,688USD£2,078GBP
€3495EUR$3,840USD£2,969GBP
- Book
- June 2015
- 392 Pages
The Pneumococcal Vaccine is a type of vaccine used to protect against infection caused by the bacterium Streptococcus pneumoniae. It is used to prevent a range of illnesses, including pneumonia, meningitis, and sepsis. The vaccine is typically administered to infants and young children, as well as adults who are at an increased risk of infection. It is also recommended for adults over the age of 65.
The Pneumococcal Vaccine market is a subset of the larger Vaccines market. It is a highly competitive market, with a number of companies offering different types of vaccines. These companies are typically involved in the research, development, and production of the vaccines. They also provide support services such as distribution, marketing, and education.
Some of the companies in the Pneumococcal Vaccine market include Pfizer, Merck, GlaxoSmithKline, Sanofi, and Novartis. Show Less Read more